GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Current Ratio

Synthorx (Synthorx) Current Ratio : 18.87 (As of Sep. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Synthorx Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Synthorx's current ratio for the quarter that ended in Sep. 2019 was 18.87.

Synthorx has a current ratio of 18.87. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Synthorx's Current Ratio or its related term are showing as below:

THOR's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.77
* Ranked among companies with meaningful Current Ratio only.

Synthorx Current Ratio Historical Data

The historical data trend for Synthorx's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx Current Ratio Chart

Synthorx Annual Data
Trend Dec16 Dec17 Dec18
Current Ratio
18.02 4.23 26.99

Synthorx Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Current Ratio Get a 7-Day Free Trial Premium Member Only 11.21 26.99 22.15 22.77 18.87

Competitive Comparison of Synthorx's Current Ratio

For the Biotechnology subindustry, Synthorx's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synthorx's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's Current Ratio distribution charts can be found below:

* The bar in red indicates where Synthorx's Current Ratio falls into.



Synthorx Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Synthorx's Current Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Current Ratio (A: Dec. 2018 )=Total Current Assets (A: Dec. 2018 )/Total Current Liabilities (A: Dec. 2018 )
=190.044/7.042
=26.99

Synthorx's Current Ratio for the quarter that ended in Sep. 2019 is calculated as

Current Ratio (Q: Sep. 2019 )=Total Current Assets (Q: Sep. 2019 )/Total Current Liabilities (Q: Sep. 2019 )
=157.66/8.357
=18.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synthorx  (NAS:THOR) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Synthorx Current Ratio Related Terms

Thank you for viewing the detailed overview of Synthorx's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Synthorx (Synthorx) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037
Executives
Powell Andrew Kenneth William director C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver director, officer: President and CEO 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022